Helping To Bring Hematologic Oncology Therapies To Cancer Patients

Catalyst Oncology is a specialized oncology CRO dedicated exclusively to advancing next-generation therapies for hematologic malignancies. Unlike solid-tumor studies, heme/onc trials present unique scientific, operational, and safety complexities — from rapidly changing disease states to intensive sampling schedules and highly specialized response assessments — making an experienced partnership essential for success.

Catalyst invests its full focus, resources, and expertise into helping emerging biotechs navigate these challenges, accelerate proof-of-concept, and move promising therapies toward regulatory approval. Our mission is grounded in urgency and purpose: to shorten the time it takes for innovative blood cancer treatments to reach the patients and families who cannot afford to wait.